NewsRx

Search our medical news database

Cancer Gene Therapy

Bypassing Transdominant Inhibition of p53 Needed

Published in Gene Therapy Weekly, October 25th, 1999

Reversal of transdominant inhibition would improve prospects for p53 cancer gene therapy.

E.S. Stavridi and colleagues from the Wistar Institute, Pennsylvania, studied protein interactions that interfere with p53-based cancer gene therapies. Their results were presented in a recent issue of Protein Science ("Change in Oligomerization Specificity of the p53 Tetramerization Domain by Hydrophobic Amino Acid Substitutions," Protein Science, September 1999;8(9):1773-1779).

"The tumor suppressor function of the wild-type p53 protein is transdominantly inhibited by tumor-derived mutant p53 proteins," wrote Stavridi et al. "Such transdominant...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook